Anticipating and managing bleeding complications in patients with coronary stents who are receiving dual antiplatelet treatment

BMJ (Online)

Volumn 343, Issue 7817, 2011, Pages

  Bhala, Neeraj ^a,b   Taggar, Jaspal S ^c   Rajasekhar, Praveen ^d   Banerjee, Amitava ^e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d SOUTH TYNESIDE DISTRICT HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PACLITAXEL; PROTON PUMP INHIBITOR; RAPAMYCIN; TACROLIMUS; ZOTAROLIMUS; COAGULATING AGENT; DRUG DERIVATIVE; FIBRINOLYTIC AGENT; TICLOPIDINE;

BARE METAL STENT; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CONSERVATIVE TREATMENT; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DRUG ELUTING STENT; GASTROINTESTINAL ENDOSCOPY; HEART INFARCTION; HUMAN; PEPTIC ULCER; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RESTENOSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STENT THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UPPER GASTROINTESTINAL BLEEDING; VASCULAR ACCESS; BLOOD COMPONENT THERAPY; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG INTERACTION; FORECASTING; GASTROINTESTINAL HEMORRHAGE; INDWELLING CATHETER; METHODOLOGY; PRACTICE GUIDELINE; RISK FACTOR; STENT; TREATMENT OUTCOME;

BLOOD COMPONENT TRANSFUSION; CATHETERS, INDWELLING; COAGULANTS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; ENDOSCOPY, GASTROINTESTINAL; FIBRINOLYTIC AGENTS; FORECASTING; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROTON PUMP INHIBITORS; RISK FACTORS; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 79960936853     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d4264     Document Type: Review

References (30)

1. Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev 2010;5:CD004587.
2. National Institute for Health and Clinical Excellence. Drug-eluting stents for the treatment of coronary artery disease. Technology Appraisal Guidance 152. 2008. www.nice.org.uk/nicemedia/pdf/TA152Guidance.pdf.
3. Meads C, Cummins C, Jolly K, Stevens A, Burls A, Hyde C. Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. Health Technol Assess 2000;4:1-153.
4. Ludman P. BCIS - British Cardiovascular Intervention Society. BCIS audit returns. Adult interventional procedures. Jan 2008 to Dec 2008. 2009. www.bcis.org.uk/resources/documents/BCIS%20Audit%202008%20for%20web%2016-10- 09%20version%201.pdf.
5. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005;111:2906-12. (Pubitemid 40823048)
6. Naik H, White AJ, Chakravarty T, Forrester J, Fontana G, Kar S, et al. A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis. JACC Cardiovasc Interv 2009;2:739-47.
7. From AM, Al Badarin FJ, Cha SS, Rihal CS. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis of data from the ARTS II, CARDia, ERACI III, and SYNTAX studies and systematic review of observational data. EuroIntervention 2010;6:269-76.
8. Bavry AA, Bhatt DL. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet 2008;371:2134-43. (Pubitemid 351842583)
9. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9. (Pubitemid 46376802)
10. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30. (Pubitemid 40617065)
11. Antithrombotic Trialists' (ATT) Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
12. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33. (Pubitemid 32772726)
13. Sorensen R, Abildstrom SZ, Weeke P, Fosbol EL, Folke F, Hansen ML, et al. Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study. BMC Cardiovasc Disord 2010;10:6.
14. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
15. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial 38. Lancet 2009;373:723-31.
16. Neuner M, Davis J. How to reverse an antithrombotic agent. Emergency Medicine 2011. www.emedmag.com/html/pre/fea/features/041060008.asp.
17. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium 1. Circulation 2011;123:2736-47.
18. Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv 2011;4:191-7.
19. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score 1. Circulation 2009;119:1873-82.
20. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010;55:2556-66.
21. Agostoni P, Biondi-Zoccai GG, De Benedictis ML, Rigattieri S, Turri M, Anselmi M, et al. Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol 2004;44:349-56. (Pubitemid 38950594)
22. Archbold RA, Robinson NM, Schilling RJ. Radial artery access for coronary angiography and percutaneous coronary intervention. BMJ 2004;329:443-6. (Pubitemid 39141482)
23. Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial 1. Lancet 2011;377:1409-20.
24. Muller DW, Shamir KJ, Ellis SG, Topol EJ. Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. Am J Cardiol 1992;69:63-8.
25. Wong EM, Wu EB, Chan WW, Yu CM. A review of the management of patients after percutaneous coronary intervention. Int J Clin Pract 2006;60:582-9.
26. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
27. Serebruany VL, Malinin AI, Ferguson JJ, Vahabi J, Atar D, Hennekens CH. Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundam Clin Pharmacol 2008;22:315-21.
28. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
29. Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 2003;34:2060-5. (Pubitemid 36944806)
30. Al-Shahi SR, Labovitz DL, Stapf C. Spontaneous intracerebral haemorrhage 1. BMJ 2009;339:b2586.